Please read and agree to the
terms and conditions
of this site.
I agree
COVID-19
/news
Clear filters and search
Format
photo
Tags
/markets
/money
markets
money
What
currently
18
×
opportunity
18
×
pandemic
18
×
stock
trades
18
×
believe
coronavirus
fact
february
good
hit
present
time
covid
pre
world
high
near
beginning
buying
traded
buy
level
moment
seen
year
decent
far
levels
march
best
close
known
pharmaceutical
rebound
ride
set
surpass
volatile
altria
Language
unset
Current search:
pandemic
×
opportunity
×
currently
×
trades
×
@forbes.com
3 years ago
Is AT&T Stock A Bargain At $25?
@forbes.com
3 years ago
Kirby Stock Performance In The Pandemic vs 2008
@forbes.com
4 years ago
Should You Buy uniQure Stock At $30?
@forbes.com
4 years ago
AT&T Stock Will Not Go Back To Its Pre-Covid High
@forbes.com
4 years ago
Molson Coors Stays Flat As Market Rises, But The Tide Is Set To Turn
@forbes.com
3 years ago
Should You Buy Baxter Stock Around $80?
@forbes.com
3 years ago
Will Teva Stock Rebound After A 10% Fall In A Month?
@forbes.com
4 years ago
PepsiCo Stock To Surpass Its Pre-Covid Level
@forbes.com
4 years ago
Dish Network Stock Set For A 25% Gain?
@forbes.com
4 years ago
AT&T: Stock With 20% Growth Potential
@forbes.com
3 years ago
Vertex Pharmaceuticals Stock Is Likely To Rebound From $180 Levels Currently
@forbes.com
4 years ago
Should You Buy Xerox Stock At $24 Levels?
@forbes.com
4 years ago
Cedar Fair Stock Recovers 126% – Has It Peaked?
@forbes.com
4 years ago
Should You Buy CVS Health Stock At $70?
@forbes.com
3 years ago
Is A Recovery Imminent In Haemonetics Stock After Falling 40% This Year?
@forbes.com
4 years ago
Should You Buy BioMarin Pharmaceutical Stock At $78?
@forbes.com
4 years ago
Can Altria Stock Surpass Its Pre-Covid Level?
@forbes.com
4 years ago
Stock Offering 60% Upside: Strategic Education